Jump to ContentJump to Main Navigation

Clinical Chemistry and Laboratory Medicine (CCLM)

Published in Association with the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)

Editor-in-Chief: Plebani, Mario

Ed. by Gillery, Philippe / Lackner, Karl J. / Lippi, Giuseppe / Melichar, Bohuslav / Schlattmann, Peter / Tate, Jillian R. / Tsongalis, Gregory J.

14 Issues per year

IMPACT FACTOR 2014: 2.707
Rank 6 out of 30 in category Medical Laboratory Technology in the 2014 Thomson Reuters Journal Citation Report/Science Edition

SCImago Journal Rank (SJR) 2014: 0.741
Source Normalized Impact per Paper (SNIP) 2014: 1.011
Impact per Publication (IPP) 2014: 2.310



Recent progress and clinical importance on pharmacogenetics in cancer therapy

Thomas I. Peng Soh1 / Wei Peng Yong1 / 2

1Department of Hematology-Oncology, National University Cancer Institute, Singapore

2University of North Carolina at Chapel Hill, Institute for Pharmacogenomics and Individualized Therapy, Chapel Hill, NC, USA

Corresponding author: Federico Innocenti, MD, PhD, University of North Carolina at Chapel Hill, Institute for Pharmacogenomics and Individualized Therapy, 1014 Genetic Medicine Bldg. CB 7361, 120 Mason Farm Rd. Chapel Hill, NC 27599-7361, USA Phone: +1-919-966-9422, Fax: +1-919-966-5863

Citation Information: Clinical Chemistry and Laboratory Medicine. Volume 49, Issue 10, Pages 1621–1632, ISSN (Online) 1437-4331, ISSN (Print) 1434-6621, DOI: 10.1515/CCLM.2011.715, September 2011

Publication History

Published Online:


Recent advances have provided unprecedented opportunities to identify prognostic and predictive markers of efficacy of cancer therapy. Genetic markers can be used to exclude patients who will not benefit from therapy, exclude patients at high risk of severe toxicity and adjust dosing. Genomic approaches for marker discovery now include genome-wide association studies and tumor DNA sequencing. The challenge is now to select markers for which there is enough evidence to transition them to the clinic. The hurdles include the inherent low frequency of many of these markers, the lengthy validation process through trials, as well as legislative and economic hurdles. Attempts to answer questions about certain markers more quickly have led to an increased popularity of trials with enrichment design, especially in light of the dramatic phase I results seen in recent months. Personalized medicine in oncology is a step closer to reality.

Keywords: biomarkers; cancer therapy; pharmacogenetics

Comments (0)

Please log in or register to comment.